The 3D screen print has proven to be a powerful additive manufacturing technology that enables the large-scale production of complex technical ceramic components. Companies such as Exentis Group AG and Axenoll Life Sciences AG, both in Switzerland, are leading innovations in this area and apply their expertise in industries that range from pharmaceuticals and energy to biotechnology and medical applications.
For those who are not familiar with it, the 3D screen print is an added process that builds complex components layer by layer by pressing a printable suspension of fine powder and binder via a computer-generated mask. Each layer is hardened before the next one is used, creating an exact three -dimensional structure.
This method works at room temperature without laser and makes it energy -efficient and scalable for industrial production. It supports ceramics, metals, polymers and biomaterials and enables applications in pharmaceuticals, medical bioprinting and technical ceramics. The technology is often used for mass production of medicinal tablets, microfluidic chips and high -strength ceramic components that offer high precision, material versatility and cost efficiency.
3D screen printing in exentis in industry in the industrial scale
Exentis Group AG has developed a unique 3D screen printing technology that supports the production of millions of components annually. This platform offers various materials, including ceramics, metals, polymers and biomaterials, and offers applications in pharmaceuticals, energy and ultra-enemy structures.
The company's additive manufacturing process uses screen printing technology to press a printable metal or ceramic powder suspension via a computer-generated mask, followed by a hardening step. This layer-for-shift process works at room temperature without laser and makes it both energy-efficient and environmentally friendly and at the same time preserves material integrity.
In addition to the technical ceramics, Exentis technology enables mass production of over 200 million tailor -made tablets per year, which are tailored to controlled drug release. The platform can also generate ultra -fine ceramic structures with wall thicknesses below 50 micrometers that are directed for the industries that require extreme precision.
With a turnover of CHF 18.6 million in 2023, which marked the growth of 23% compared to the previous year -house production or outourcing in large -scale production in their facilities.
Axenolls medical and biotechnological 3D printing
Axenoll Life Sciences AG focuses on the 3D screen printing for medical and biotechnological applications. The 3D mass adaptation technology enables high-resolution, reproducible production under Good Manufacturing Practice (GMP) and sterile conditions. In contrast to conventional methods, this approach integrates directly living cells and biomaterials into 3D -printed structures.
Axenoll applications include microfluidic chips, wound associations and cosmetic products. His gentle bioprinting process ensures that viable cells in printed structures remain intact, which it is ideal for biomedical and life science applications. The company also offers OEM production, research and development services as well as proprietary product development.
The company operates through its subsidiary Axenoll 3D -Druck GmbH in Jena and works with industrial and academic partners worldwide. In July 2021, Axenoll secured a risk capital investment of 8.26 million US dollars to expand its biomaterial 3D printing technology.